- Home
- MYGN vs TAC Comparison
MYGN vs TAC Comparison
Compare MYGN & TAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TAC
- Stock Information
- Founded
- MYGN 1991
- TAC 1909
- Country
- MYGN United States
- TAC Canada
- Employees
- MYGN N/A
- TAC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TAC Electric Utilities: Central
- Sector
- MYGN Health Care
- TAC Utilities
- Exchange
- MYGN Nasdaq
- TAC Nasdaq
- Market Cap
- MYGN 2.2B
- TAC 2.2B
- IPO Year
- MYGN 1995
- TAC N/A
- Fundamental
- Price
- MYGN $26.43
- TAC $10.46
- Analyst Decision
- MYGN Buy
- TAC
- Analyst Count
- MYGN 12
- TAC 0
- Target Price
- MYGN $28.18
- TAC N/A
- AVG Volume (30 Days)
- MYGN 651.3K
- TAC 732.3K
- Earning Date
- MYGN 11-04-2024
- TAC 11-05-2024
- Dividend Yield
- MYGN N/A
- TAC 1.71%
- EPS Growth
- MYGN N/A
- TAC 102.13
- EPS
- MYGN N/A
- TAC 1.40
- Revenue
- MYGN $802,200,000.00
- TAC $2,316,150,952.00
- Revenue This Year
- MYGN $13.84
- TAC N/A
- Revenue Next Year
- MYGN $9.57
- TAC N/A
- P/E Ratio
- MYGN N/A
- TAC $7.49
- Revenue Growth
- MYGN 14.78
- TAC N/A
- 52 Week Low
- MYGN $13.82
- TAC $5.94
- 52 Week High
- MYGN $29.30
- TAC $10.61
- Technical
- Relative Strength Index (RSI)
- MYGN 44.56
- TAC 75.18
- Support Level
- MYGN $25.90
- TAC $10.26
- Resistance Level
- MYGN $27.55
- TAC $10.61
- Average True Range (ATR)
- MYGN 0.88
- TAC 0.27
- MACD
- MYGN -0.07
- TAC 0.04
- Stochastic Oscillator
- MYGN 15.59
- TAC 89.87
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse and growing fleet of electrical power generation assets in Canada, the United States, and Australia. The company has six reportable segments namely, hydro, wind & solar, Energy Marketing, gas, energy transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.